Effect of in Vitro Haemolysis on Serum High Sensitivity Troponin T Measurements From Patients in Accident & Emergency
NCT ID: NCT03439605
Last Updated: 2018-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
61 participants
OBSERVATIONAL
2017-09-09
2017-12-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Distribution of Highly Sensitive Troponin in the Critically Unwell & Associated Mortality
NCT03630237
Hemorrhagic Myocardial Infarction Detection by Post-reperfusion Troponin Kinetics
NCT05872308
Perioperative Myocardial Ischemia: Troponin Monitoring,Cost-effectiveness, Insights Into Pathophysiology
NCT03438448
Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography
NCT03952351
Coronary Collaterals and Post-reperfusion Intramyocardial Hemorrhage
NCT05898425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will be conducted as a Masters research project in Biomedical sciences (Clinical Biochemistry) as well as providing evidence to evaluate current laboratory practice. Participants attending Poole Hospital accident and emergency who are already having blood samples taken for the heart damage blood test, high sensitivity Troponin T (hs-cTnT), are chosen for this study. As the participants are already having the hs-cTnT blood test performed it means the investigators will not be determining any new information about them from the tests and they are also the population that the results of the study will benefit.
Whilst the participants are having the routine blood samples taken for their medical investigation, an extra two blood samples will be collected (a maximum of 9 ml; less than two teaspoons) following verbal permission. Only patients with the capacity to give verbal consent will be included in the study and then their blood will only be taken once. The extra blood samples will be labelled with the time and date of collection (to ensure stability when analysing). No patient identifying information will be written on the samples and they will be sent to the laboratory in a separate bag from the routine specimens to ensure anonymity.
Once received in the laboratory, one of the study samples will be analysed for hs-cTnT and haemolysis index (a measured value that equates to the amount of haemoglobin in the sample and therefore red blood cell damage). The results from these initial tests will determine if the hs-cTnT and haemolysis are within the desired range for the study.
If the sample meets the requirements for the study, a sample specific haemolysate (Haemolysed serum) will be created from the second sample. Using both samples, varying controlled degrees of haemolysis will be created and then tested for hs-cTnT. The results from the varying degrees of haemolysis will be compared to the original unhaemolysed result to determine whether a significant change in the result has occurred.
Null hypotheses:
* There is no significant difference in hs-cTnT results between baseline and up to 100 haemolysis index. There is a significant difference in hs-cTnT results between baseline and all haemolysis index levels greater than 100.
* There is no significant difference in mean percentage change of hs-cTnT up to 100 Haemolysis index and there is a significant difference in mean percentage change of hs-cTnT at all Haemolysis levels greater than 100 haemolysis index.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Serum High sensitivity Troponin T result \<5 ng/l and \>100 ng/l
* Patients lacking capacity to give verbal consent.
* Under 18 years of age.
* Patient has previously been approached about this study.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poole Hospital NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Poole Hospital NHSFT
Poole, Dorset, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP170327
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.